Active Ingredient: SELPERCATINIB
Proprietary Name: RETEVMO
Dosage Form; Route of Administration: CAPSULE; ORAL
Strength: 80MG
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N213246
Product Number: 002
Approval Date: May 8, 2020
Applicant Holder Full Name: LOXO ONCOLOGY INC A WHOLLY OWNED SUB OF ELI LILLY AND CO
Marketing Status:
Prescription
Patent and Exclusivity Information
